Small biotech chaired by ex-Purdue CEO Mark Timney jumps into the SPAC lane
The latest biotech SPAC has landed, and it’s one featuring Purdue Pharma’s former CEO, Mark Timney.
Blade Therapeutics announced its plans Monday to reverse merge with the bluntly named Biotech Acquisition Company in a $254.3 million deal. Timney, who currently serves as Blade’s executive chairman, will retain the same role once the combined company completes the merger in the first quarter of 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.